These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 306851)

  • 21. High-dose methotrexate in osteogenic sarcoma: a 5-year experience.
    Jaffe N; Frei E; Watts H; Traggis D
    Cancer Treat Rep; 1978 Feb; 62(2):259-64. PubMed ID: 346215
    [No Abstract]   [Full Text] [Related]  

  • 22. Pathologic aspects of chemotherapy response in the treatment of osteogenic sarcoma. An analysis of two cases.
    Marroum MC; Huvos AG; Rosen G
    Oncology; 1977; 34(6):273-80. PubMed ID: 304199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma.
    Rosen G; Tan C; Sanmaneechai A; Beattie EJ; Marcove R; Murphy ML
    Cancer; 1975 Mar; 35(3 suppl):936-45. PubMed ID: 1078642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [H-MTX-CF treatment and osteogenic sarcoma (author's transl)].
    Goto M
    Hokkaido Igaku Zasshi; 1981 Mar; 56(2):235. PubMed ID: 6976923
    [No Abstract]   [Full Text] [Related]  

  • 25. "Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.
    Von Hoff DD; Rozencweig M; Louie AC; Bender RA; Muggia FM
    Cancer Treat Rep; 1978 Feb; 62(2):233-5. PubMed ID: 305823
    [No Abstract]   [Full Text] [Related]  

  • 26. Adjuvant chemotherapy for osteogenic sarcoma.
    Etcubanas E; Wilbur JR
    Cancer Treat Rep; 1978 Feb; 62(2):283-7. PubMed ID: 346218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Chemotherapy of osteosarcoma (author's transl)].
    Winkler K; Gaedicke G; Grosch-Wörner I; Marsmann G; Delling G; Landbeck G
    Dtsch Med Wochenschr; 1977 Dec; 102(50):1831-5. PubMed ID: 303980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)].
    Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M
    Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The results of using high-dose methotrexate in treating osteogenic sarcoma].
    Perevodchikova NI; Eremina LA; Manziuk LV; Siniukov PA; Fedenko AN; Singin AS; Moldovanova LK
    Vopr Onkol; 1990; 36(6):667-71. PubMed ID: 2378085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
    Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
    Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.
    Rosen G; Caparros B; Huvos AG; Kosloff C; Nirenberg A; Cacavio A; Marcove RC; Lane JM; Mehta B; Urban C
    Cancer; 1982 Mar; 49(6):1221-30. PubMed ID: 6174200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteogenic sarcoma: state of the art with high-dose methotrexate treatment.
    Jaffe N
    Clin Orthop Relat Res; 1976 Oct; (120):95-102. PubMed ID: 1086179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.
    Huvos AG; Rosen G; Marcove RC
    Arch Pathol Lab Med; 1977 Jan; 101(1):14-8. PubMed ID: 299812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
    Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
    Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemistry of the citrovorum factor rescue effect in normal bone marrow cells after high-dose methotrexate treatment: implications for therapy.
    Wilmans W; Sauer W; Schalhorn A
    Recent Results Cancer Res; 1978; 68():33-9. PubMed ID: 313587
    [No Abstract]   [Full Text] [Related]  

  • 36. High-dose methotrexate with a safe rescue program.
    Decker DA; Edmonson JH; Gilchrist GS; Kovach JS; Offord JR; Taylor WF
    Oncology; 1981; 38(5):262-4. PubMed ID: 6973732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New therapeutic results in osteosarcoma].
    Urban C; Rosen G
    Wien Med Wochenschr; 1982 Jul; 132(13-14):335-41. PubMed ID: 6982567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
    Cohen IJ
    Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy.
    Rosen G; Marcove RC; Huvos AG; Caparros BI; Lane JM; Nirenberg A; Cacavio A; Groshen S
    J Cancer Res Clin Oncol; 1983; 106 Suppl():55-67. PubMed ID: 6604058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Radiational basis and practice of the citrovorum factor (Leucovorin) protection after high-dose methotrexate therapy. High-dose methotrexate/leucovorin].
    Sauer H; Schalhorn A
    Onkologie; 1980 Apr; 3(2):64-71. PubMed ID: 6994007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.